reports
Krystal Biotech Inc: 1 director
A director at Krystal Biotech Inc sold/sold after exercising options 60,161 shares at 267.270USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Confere...
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Company’s . About Krystal Biotech, In...
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial ...
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results $107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business ...
AZZ Inc: 1 director
A director at AZZ Inc sold 2,923 shares at 136.000USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial ...
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For those u...
TD Synnex Corp: 1 director
A director at TD Synnex Corp sold 13,900 shares at 171.570USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for...
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 and interleukin-12 in the tumor microenvironment, for the treatment of advanced or metastatic non-small cell lung cancer (NS...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of TD SYNNEX Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 26 January 2026 in which we reassessed the appropriateness of the ratings in the cont...
- Dave Nicoski
- Ross LaDuke
OXY OCCIDENTAL PETROLEUM CORPORATION
AMN AMN HEALTHCARE SERVICES INC.
PPC PILGRIM'S PRIDE CORPORATION
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
LAND GLADSTONE LAND CORP.
JCOM J2 GLOBAL INC.
JACK JACK IN THE BOX INC.
IPAR INTER PARFUMS INC.
INGR INGREDION INCORPORATED
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
EXPO EXPONENT INC.
EPC EDGEWELL PERSONAL CARE CO.
EMN EASTMAN CHEMICAL COMPANY
CLX CLOROX COMPANY
CE CELANESE CORPORATION
ACCO ACCO BRANDS CORPORATION
HRI HERC HOLDINGS INC.
OFLX OMEGA FLEX
WDFC WD-40 COMPANY
BOOM DMC GLOBAL INC
UAA UNDER ARMOUR INC. CLASS A
NHF NEXPOINT CREDIT STRATEGIES FUN
IOVA IOVANCE BIOTHERAPEUTICS INC
FNKO FUNKO CLASS A
SPB SPECTRUM BRANDS HOLDINGS INC.
AVNS AVANOS MEDICAL INC.
DOW DOW INC.
AMCR AMCOR PLC
ATEX ANTERIX INC
BJ BJ'S WHOLESALE CLUB HOLDINGS
NVAX NOVAVAX INC.
VIR VIR BIOTECHNOLOGY
ALT ALTIMMUNE INC
NKTX NKARTA
PTLO PORTILLOS INC
CHRD CHORD ENERGY CORPORATION
LIN LINDE PUBLIC LIMITED COMPANY
HUN GLOBAL X NATURAL GAS ETF
INR INFINITY NATURAL RESOURCES INC
MUSA MIDDLEFIELD US EQUITY DIV ET ETF UN
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan He...
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company’s strategic vision to drive the next stage of growth of its rare diseas...
Krystal Biotech Announces Positive Interim Clinical Update from KB407 ...
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective of modulator-status; percentage of conducting airway cells transduced in each patient ranged from 29.4% to 42.1% Registrational repeat dosing CORAL-3 study design submitted to FDA in late December; anticipat...
Krystal Biotech to Announce Interim Clinical Update from Highest Dose ...
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis Investor call to be held January 8 at 4:30 pm ET to discuss data update and next steps PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update from CORAL-1, the Company’s multi-center, dose escalation Phase 1 study evaluating KB407 in patients with cyst...
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Confe...
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a presentation at 10:30 am ET / 7:30 am PT and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:30 am ET / 7:30 am PT on Monday, January 12, 2026 and will be po...
- Jonathan Moreland
ITW ILLINOIS TOOL WORKS INC.
AAON AAON INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
CUBE CUBESMART
CLFD CLEARFIELD INC.
CE CELANESE CORPORATION
APLE APPLE HOSPITALITY REIT INC
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
OXM OXFORD INDUSTRIES INC.
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
WMG WARNER MUSIC GROUP CORP.
DIS THE WALT DISNEY COMPANY
NWPP NEW PEOPLES BANKSHARES INC.
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
KOD KODIAK SCIENCES
EML THE EASTERN COMPANY
MIDD THE MIDDLEBY CORPORATION
DHC DIVERSIFIED HEALTHCARE TRUST
COO THE COOPER COMPANIES INC.
RZLT REZOLUTE
AZYO INC.
NOG AZIYO BIOLOGICS
DLHC NORTHERN OIL AND GAS
IMNM DALEIGH HOLDINGS CORP
AMR IMMUNOME
BMEA ALPHA METALLURGICAL RESOURCES INC
LUCY BIOMEA FUSION
KVUE INC.
NBBK INNOVATIVE EYEWEAR INC
SI KENVUE INC
ASST NB BANCORP INC.
SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
- Jonathan Moreland
ZEUS OLYMPIC STEEL INC.
XOMA XOMA
NWBI NORTHWEST BANCSHARES INC.
NRIM NORTHRIM BANCORP INC.
MERC MERCER INTERNATIONAL INC.
MCY MERCURY GENERAL CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CRM SALESFORCE.COM INC.
CE CELANESE CORPORATION
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
AMH AMERICAN HOMES 4 RENT CLASS A
MGM MGM RESORTS INTERNATIONAL
OXM OXFORD INDUSTRIES INC.
RSG REPUBLIC SERVICES INC.
MHH MASTECH DIGITAL
WMG WARNER MUSIC GROUP CORP.
NHF NEXPOINT CREDIT STRATEGIES FUN
PMTS CPI CARD GROUP
NWPP NEW PEOPLES BANKSHARES INC.
MIDD THE MIDDLEBY CORPORATION
AVTR AVANTOR
SELF INC.
ALTG SELF STORAGE GROUP
IMVT INC.
ORIC ALTA EQUIPMENT GROUP INC.
NOG IMMUNOVANT INC
MRVI ORIC PHARMACEUTICALS
DMAC NORTHERN OIL AND GAS
AMR MARAVAI LIFESCIENCES HOLDINGS
NRDY DIAMEDICA THERAPEUTICS INC.
ABSI ALPHA METALLURGICAL RESOURCES INC
IMMX NERDY INC.
LUCY ABSCI CORP
LIN IMMIX BIOPHARMA INC
MNR INNOVATIVE EYEWEAR INC
XELB LINDE PUBLIC LIMITED COMPANY
FEAM MACH NATURAL RESOURCES LP
SEVN XCEL BRANDS INC.
5E ADVANCED MATERIALS INC.
SEVEN HILLS REALTY TRUST
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
MMLP MARTIN MIDSTREAM PARTNERS L.P.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CE CELANESE CORPORATION
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
OXM OXFORD INDUSTRIES INC.
MLP MAUI LAND & PINEAPPLE CO. INC.
WMG WARNER MUSIC GROUP CORP.
SPT SPROUT SOCIAL
IMVT INC.
NOG IMMUNOVANT INC
AMR NORTHERN OIL AND GAS
PBBK ALPHA METALLURGICAL RESOURCES INC
NRDY PB BANKSHARES
LUCY INC.
SMRT NERDY INC.
INNOVATIVE EYEWEAR INC
SMARTRENT INC
International Flavors & Fragrances Inc: 1 director
A director at International Flavors & Fragrances Inc bought 3,100 shares at 63.480USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.